在胃癌治疗中准缺氧诱导的HIF-1α/JMJD3/Notch轴
Xin She1, Lijun Geng1, Qianwen Zhao1
1Department of Clinical Laboratory, The Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China.
Journal of bioenergetics and biomembranes
|March 26, 2025
概括
在胃癌 (GC) 中发现高水平的缺氧诱导因子1-alpha (HIF-1α) 和JMJD3. 针对HIF-1α/JMJD3/Notch通路可能为GC进展提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 缺氧诱导高表达缺氧诱导因子1-α (HIF-1α) 在各种癌症,显著影响胃癌 (GC) 的进展.
- 在胃癌中HIF-1α的精确机制仍然不完全理解.
研究的目的:
- 阐明HIF-1α在胃癌进展中的机制.
- 在低氧条件下研究HIF-1α/JMJD3/Notch轴在胃癌中的作用.
- 评估这个轴作为GC治疗目标的潜力.
主要方法:
- 定量逆转录聚合酶连锁反应 (qRT-PCR) 和西部抹黑,以评估GC组织中的HIF-1α和JMJD3表达.
- 生物信息分析以评估HIF-1α预后及其与JMJD的关系3.3.
- 在体外和体内实验涉及HIF-1α沉默,JMJD3倒置/过度表达,以及在低氧状态下在GC细胞中使用马分泌酶抑制剂 (DAPT) 治疗.
- 细胞增殖,细胞亡和Notch激活的评估.
主要成果:
- 在GC组织中,HIF-1α和JMJD3都高度表达,高的HIF-1α与不良预后相关.
- 在低氧状态下,HIF-1α敲除减少了GC细胞的增殖和增加了亡,而JMJD3敲除则产生了相反的效果.
- 过度表达JMJD3促进了增殖,并通过对低氧GC细胞的Notch信号进行上调来降低了亡.
- 在GC小鼠模型中,HIF-1α敲击抑制了瘤生长.
- 通过影响GC细胞中的JMJD3/Notch轴,HIF-1α敲击抑制了增殖,并促进了亡.
结论:
- 在低氧条件下,HIF-1α/JMJD3/Notch轴在胃癌进展中起着至关重要的作用.
- 准HIF-1α/JMJD3/Notch通路为胃癌提供了一个潜在的新疗法策略.
更多相关视频
相关概念视频
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Role Of Notch Signalling In Intestinal Stem Cell Renewal
2.0K
Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.0K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K


